Poly Medicure Limited

Poly Medicure Limited

Poly Medicure Limited has informed the Exchange about statement of deviation(s) or variation(s) under Reg. 32 regarding the utilization of proceeds received from Qualified Institutions Placement (QIP). The company has raised Rs 99,999.98 lakh and has utilized the funds for the original objects of the issue without any deviation.

Poly Medicure Limited

Poly Medicure Limited has submitted a Monitoring Agency Report for the quarter ended June 30, 2026, as per SEBI regulations, detailing the utilization of proceeds from its Qualified Institutional Placement (QIP) issue.

Poly Medicure Limited

Poly Medicure Limited has published unaudited financial results for the quarter ended June 30, 2026, in newspapers Financial Express and Jansatta on August 9, 2026.

Poly Medicure Limited

Poly Medicure Limited has informed the Exchange about the resignation of a Director/KMP/SMP.

Poly Medicure Limited

Poly Medicure Limited has submitted its Investor Presentation for Q1 FY27, which includes unaudited financial results for the first quarter ended June 30, 2026.

Poly Medicure Limited

Poly Medicure Limited has informed the Exchange regarding Resignation of Ravi Prakash, Deputy Company Secretary as KMP of the company w.e.f. August 10, 2026. The company also announced unaudited financial results for the quarter ended June 30, 2026, and other corporate actions.

Poly Medicure Limited

Poly Medicure Limited has informed the Exchange regarding Grant of 1476 Options under ESOP Scheme, 2020, and approval of financial results for the first quarter ended on 30th June 2026.

Poly Medicure Limited

Poly Medicure Limited has informed the Exchange regarding Allotment of 1975 Shares under ESOP Scheme, 2020, and the Board of Directors at their meeting held on August 7, 2026, approved the allotment of 1,975 Equity Shares to its eligible employees. The company also announced its unaudited financial results for the quarter ended June 30, 2026.

Poly Medicure Limited

Poly Medicure Limited has announced its unaudited financial results for the quarter ended June 30, 2026, with revenue from operations at ₹43,109.95 lakhs and total income at ₹45,974.91 lakhs. The company has also approved the grant of 1,476 stock options under the Employee Stock Option Scheme 2020 and the allotment of 1,975 equity shares to eligible employees. Additionally, the company has re-appointed M/s Jai Prakash & Company as the Cost Auditors for the financial year 2026-27 and announced the resignation of Mr. Ravi Prakash as Deputy Company Secretary and Compliance Officer.

Poly Medicure Limited

Poly Medicure Limited has informed the Exchange about the Investors/Analyst Call for the Financial Results of First quarter ended on 30th June, 2026.

Poly Medicure Limited

Poly Medicure Limited has submitted a certificate under SEBI (Depositories and Participants) Regulations, 2018, confirming the dematerialization of securities and updating of register of members.

Poly Medicure Limited

Poly Medicure Limited has informed the Exchange about an update in relation to the proceedings before the Hon'ble Delhi High Court regarding a stamp duty matter. The company's writ petition challenging the orders passed by the Office of Collector of Stamps was listed for hearing on July 03, 2026, but no one appeared on behalf of the respondent, resulting in a stay on the operation and execution of the impugned order till the next date of hearing.

Poly Medicure Limited

Poly Medicure Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015.

Poly Medicure Limited

Poly Medicure Limited has informed the Exchange about Credit Rating- Outlook Revision and Rating Re-affirmed by CRISIL Ratings Limited. The long-term rating outlook has been revised to 'Positive' from 'Stable', and the short-term rating has been reaffirmed at Crisil A1+.

Poly Medicure Limited

Poly Medicure Limited has informed the stock exchange about the rescheduling of its previously announced investor/analyst meet. No reasons for the rescheduling or new dates were provided in this announcement. This is a procedural update regarding an engagement with the investment community.

Poly Medicure Limited

Poly Medicure Limited has informed the exchanges about a scheduled one-on-one investor/analyst meeting. Company officials will meet with Nuvama on June 25, 2026, at 3:30 PM IST for a plant visit in Faridabad. The company explicitly stated that no Unpublished Price Sensitive Information (UPSI) will be shared during the meeting. This engagement is a routine interaction with the investor community.

Poly Medicure Limited

Poly Medicure Limited has informed the Exchange about the schedule of Investors/Analysts Call/Meet.